NewAmsterdam Pharma NAMS
NASDAQ NAMS
$21.40 -0.10 (-0.49%)
As of: Oct 21, 2026 · 2:34 PM EDT

NewAmsterdam Pharma (NAMS) Operating Leases (2021 - 2026)

Updated

NewAmsterdam Pharma (NAMS) posted Operating Leases of $56,000 for Q2 2026, down 45.6% from $103,000 a year earlier.

Analysis

NewAmsterdam Pharma (NAMS) Operating Leases (2021 - 2026) Analysis & Trends

At the end of FY2025, NewAmsterdam Pharma's Operating Leases came in at $66,000, down 67.3% from FY2024.

  • Annual Operating Leases shows a four-year compound annual growth rate of -15.8% (FY2021 to FY2025).
  • In prior years, NewAmsterdam Pharma's Operating Leases was $202,000 in FY2024, $60,000 in FY2022 (-54.3%) and $131,357 in FY2021.
  • The Q2 2026 figure stands as the lowest quarterly Operating Leases since Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,135.99 Bn 1,104.58 Bn 19.71 Bn
2 Johnson & Johnson 616.90 Bn 535.42 Bn 17.26 Bn
3 AbbVie 501.56 Bn 474.68 Bn 12.70 Bn
4 Merck 367.41 Bn 321.79 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.45 Bn 235.13 Bn 12.86 Bn
7 Amgen 236.48 Bn 191.88 Bn 7.24 Bn
8 Gilead Sciences 190.56 Bn 164.76 Bn 6.22 Bn
9 Pfizer 169.46 Bn 116.11 Bn 10.94 Bn
10 NewAmsterdam Pharma 2.64 Bn 30.36 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 56,000.00
Dec 31, 2025 66,000.00
Sep 30, 2025 85,000.00
Jun 30, 2025 103,000.00
Mar 31, 2025 137,000.00
Dec 31, 2024 202,000.00
Sep 30, 2024 266,000.00
Jun 30, 2024 328,000.00
Jun 30, 2023 24,996.47
Dec 31, 2022 59,700.22
Dec 31, 2021 125,707.81
API Access

NewAmsterdam Pharma Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=NAMS&period=max&api_key=YOUR_API_KEY